Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Jun;63(6):718–722. doi: 10.1136/ard.2003.007104

A randomised placebo controlled trial of delipidated, deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis

N Dalbeth 1, S Yeoman 1, J Dockerty 1, J Highton 1, E Robinson 1, P Tan 1, D Herman 1, F McQueen 1
PMCID: PMC1755035  PMID: 15140780

Abstract

Objectives: To test the hypothesis that PVAC, delipidated, deglycolipidated heat killed Mycobacterium vaccae, is an effective and safe treatment for psoriatic arthritis (PsA). This treatment has shown promising results in psoriasis.

Methods: 36 patients with PsA in two centres were studied in this double blind, placebo controlled, randomised trial. Patients were randomised to receive two intradermal injections of 50 µg PVAC or placebo and were followed up for 24 weeks. The primary end point was the Psoriatic Arthritis Response Criteria (PsARC), a composite measure based on changes in joint tenderness and swelling scores and physician and patient global assessments.

Results: The PsARC response at either 12 or 24 weeks was achieved by 9/18 (50%) placebo and 9/18 (50%) PVAC patients (p = 1.0). No significant differences in the Psoriasis Activity and Severity Index (PASI), patient or physician global assessments, CRP, or Health Assessment Questionnaire score over time were found between the two groups. However, changes in the pain visual analogue scale over time did differ between the two groups (p = 0.006): at 24 weeks the mean score in the PVAC group had declined by 19.2 mm and in the placebo group had increased by 4.8 mm. PVAC was well tolerated with no increased incidence of adverse events compared with placebo.

Conclusions: PVAC was not shown to be as effective as immunotherapy for PsA. The striking response to placebo in this study reinforces the importance of adequately controlling therapeutic trials in PsA.

Full Text

The Full Text of this article is available as a PDF (75.4 KB).

Figure 1 .

Figure 1

Open in a new tab

Change in pain visual analogue score (VAS) over time. Week 24, PVAC v placebo, p = 0.006)

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asadullah K., Sterry W., Stephanek K., Jasulaitis D., Leupold M., Audring H., Volk H. D., Döcke W. D. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest. 1998 Feb 15;101(4):783–794. doi: 10.1172/JCI1476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Balagon M. V., Tan P. L., Prestidge R., Cellona R. V., Abalos R. M., Tan E. V., Walsh G. P., Watson J. D., Walsh D. S. Improvement in psoriasis after intradermal administration of delipidated, deglycolipidated Mycobacterium vaccae (PVAC): results of an open-label trial. Clin Exp Dermatol. 2001 May;26(3):233–241. doi: 10.1046/j.1365-2230.2001.00804.x. [DOI] [PubMed] [Google Scholar]
  3. Barker J. N. The immunopathology of psoriasis. Baillieres Clin Rheumatol. 1994 May;8(2):429–438. doi: 10.1016/s0950-3579(94)80027-8. [DOI] [PubMed] [Google Scholar]
  4. Choy E. H., Scott D. L., Kingsley G. H., Thomas S., Murphy A. G., Staines N., Panayi G. S. Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum. 2001 Sep;44(9):1993–1997. doi: 10.1002/1529-0131(200109)44:9<1993::AID-ART347>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  5. Clegg D. O., Reda D. J., Mejias E., Cannon G. W., Weisman M. H., Taylor T., Budiman-Mak E., Blackburn W. D., Vasey F. B., Mahowald M. L. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996 Dec;39(12):2013–2020. doi: 10.1002/art.1780391210. [DOI] [PubMed] [Google Scholar]
  6. Cohen M. R., Reda D. J., Clegg D. O. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol. 1999 Aug;26(8):1752–1756. [PubMed] [Google Scholar]
  7. Espinoza L. R., Zakraoui L., Espinoza C. G., Gutiérrez F., Jara L. J., Silveira L. H., Cuéllar M. L., Martínez-Osuna P. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol. 1992 Jun;19(6):872–877. [PubMed] [Google Scholar]
  8. Farr M., Kitas G. D., Waterhouse L., Jubb R., Felix-Davies D., Bacon P. A. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol. 1990 Feb;29(1):46–49. doi: 10.1093/rheumatology/29.1.46. [DOI] [PubMed] [Google Scholar]
  9. Felson D. T., Anderson J. J., Boers M., Bombardier C., Chernoff M., Fried B., Furst D., Goldsmith C., Kieszak S., Lightfoot R. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993 Jun;36(6):729–740. doi: 10.1002/art.1780360601. [DOI] [PubMed] [Google Scholar]
  10. Fredriksson T., Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244. doi: 10.1159/000250839. [DOI] [PubMed] [Google Scholar]
  11. Gladman D. D. Natural history of psoriatic arthritis. Baillieres Clin Rheumatol. 1994 May;8(2):379–394. doi: 10.1016/s0950-3579(94)80024-3. [DOI] [PubMed] [Google Scholar]
  12. Husted J. A., Gladman D. D., Farewell V. T., Cook R. J. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001 Apr;45(2):151–158. doi: 10.1002/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  13. Lehrer A., Bressanelli A., Wachsmann V., Bottasso O., Bay M. L., Singh M., Stanford C., Stanford J. Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis. FEMS Immunol Med Microbiol. 1998 May;21(1):71–77. doi: 10.1111/j.1574-695X.1998.tb01151.x. [DOI] [PubMed] [Google Scholar]
  14. Link H., Huang Y. M., Masterman T., Xiao B. G. Vaccination with autologous dendritic cells: from experimental autoimmune encephalomyelitis to multiple sclerosis. J Neuroimmunol. 2001 Mar 1;114(1-2):1–7. doi: 10.1016/s0165-5728(01)00247-8. [DOI] [PubMed] [Google Scholar]
  15. McInnes I. B., Illei G. G., Danning C. L., Yarboro C. H., Crane M., Kuroiwa T., Schlimgen R., Lee E., Foster B., Flemming D. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol. 2001 Oct 1;167(7):4075–4082. doi: 10.4049/jimmunol.167.7.4075. [DOI] [PubMed] [Google Scholar]
  16. Mease P. J., Goffe B. S., Metz J., VanderStoep A., Finck B., Burge D. J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29;356(9227):385–390. doi: 10.1016/S0140-6736(00)02530-7. [DOI] [PubMed] [Google Scholar]
  17. Moreland L. W., Morgan E. E., Adamson T. C., 3rd, Fronek Z., Calabrese L. H., Cash J. M., Markenson J. A., Matsumoto A. K., Bathon J., Matteson E. L. T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides. Arthritis Rheum. 1998 Nov;41(11):1919–1929. doi: 10.1002/1529-0131(199811)41:11<1919::AID-ART5>3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  18. O'Connell P. G., Gerber L. H., Digiovanna J. J., Peck G. L. Arthritis in patients with psoriasis treated with gamma-interferon. J Rheumatol. 1992 Jan;19(1):80–82. [PubMed] [Google Scholar]
  19. Shbeeb M., Uramoto K. M., Gibson L. E., O'Fallon W. M., Gabriel S. E. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol. 2000 May;27(5):1247–1250. [PubMed] [Google Scholar]
  20. Veale D., Yanni G., Rogers S., Barnes L., Bresnihan B., Fitzgerald O. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum. 1993 Jul;36(7):893–900. doi: 10.1002/art.1780360705. [DOI] [PubMed] [Google Scholar]
  21. Weiner Howard L., Selkoe Dennis J. Inflammation and therapeutic vaccination in CNS diseases. Nature. 2002 Dec 19;420(6917):879–884. doi: 10.1038/nature01325. [DOI] [PubMed] [Google Scholar]
  22. Wrone-Smith T., Nickoloff B. J. Dermal injection of immunocytes induces psoriasis. J Clin Invest. 1996 Oct 15;98(8):1878–1887. doi: 10.1172/JCI118989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. de Waal Malefyt R., Abrams J., Bennett B., Figdor C. G., de Vries J. E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991 Nov 1;174(5):1209–1220. doi: 10.1084/jem.174.5.1209. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES